• Je něco špatně v tomto záznamu ?

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

S. Zeuzem, L. Serfaty, J. Vierling, W. Cheng, J. George, J. Sperl, S. Strasser, H. Kumada, P. Hwang, M. Robertson, J. Wahl, E. Barr, R. Talwani, H. Platt,

. 2018 ; 53 (5) : 679-688. [pub] 20180117

Jazyk angličtina Země Japonsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028612
E-zdroje Online Plný text

NLK ProQuest Central od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 1998-02-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-03-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem
Family Health Database (ProQuest) od 1997-03-01 do Před 1 rokem

Odkazy

PubMed 29344726
DOI 10.1007/s00535-018-1429-3
Knihovny.cz E-zdroje

BACKGROUND: Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV). We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 countries who received elbasvir/grazoprevir for 12 weeks. METHODS: This is a retrospective analysis of data from participants with chronic HCV GT1b infection enrolled in 11 phase II/III clinical trials. All participants received elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks. The primary end point of all studies was sustained virologic response 12 weeks after completion of therapy (SVR12, HCV RNA < 15 IU/ml). RESULTS: SVR12 was 97.2% (1040/1070). Of the 30 participants who failed to attain SVR12, 15 relapsed and 15 had nonvirologic failure. Among participant subgroups, SVR12 was high in those with compensated cirrhosis (188/189, 99.5%), HIV co-infection (51/54, 94.4%), and baseline viral load > 800,000 IU/ml (705/728, 96.8%). Resistance-associated substitutions (RASs) at NS5A positions 28, 30, 31, or 93 were present in 21.6% of participants at baseline. SVR12 was 99.6% (820/823) in participants without baseline NS5A RASs and 94.7% (215/227) in those with baseline NS5A RASs. Serious adverse events occurred in 3.2% (34/1070) of participants, nine of which occurred after study medication was completed. CONCLUSIONS: Elbasvir/grazoprevir for 12 weeks represents an effective treatment option for participants with HCV GT1b infection. SVR12 was high in all participant subgroups, including those with compensated cirrhosis, HIV co-infection, and high baseline viral load. CLINICALTRIALS. GOV IDENTIFIERS: The trials discussed in this paper were registered with Clinicaltrial.gov as the following: NCT02092350 (C-SURFER), NCT02105662 (C-EDGE Co-Infection), NCT02105467 (C-EDGE treatment-naive), NCT02105701 (C-EDGE treatment-experienced), NCT01717326 (C-WORTHy), NCT02251990 (C-CORAL), NCT02105688 (C-EDGE COSTAR), NCT02252016 (C-EDGE IBLD), NCT02115321 (C-SALT), NCT02203149 (Japan phase 2/3 study), NCT02358044 (C-EDGE Head-2-Head).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028612
003      
CZ-PrNML
005      
20200330160246.0
007      
ta
008      
190813s2018 ja f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00535-018-1429-3 $2 doi
035    __
$a (PubMed)29344726
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ja
100    1_
$a Zeuzem, Stefan $u Goethe University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. zeuzem@em.uni-frankfurt.de.
245    14
$a The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection / $c S. Zeuzem, L. Serfaty, J. Vierling, W. Cheng, J. George, J. Sperl, S. Strasser, H. Kumada, P. Hwang, M. Robertson, J. Wahl, E. Barr, R. Talwani, H. Platt,
520    9_
$a BACKGROUND: Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV). We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 countries who received elbasvir/grazoprevir for 12 weeks. METHODS: This is a retrospective analysis of data from participants with chronic HCV GT1b infection enrolled in 11 phase II/III clinical trials. All participants received elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks. The primary end point of all studies was sustained virologic response 12 weeks after completion of therapy (SVR12, HCV RNA < 15 IU/ml). RESULTS: SVR12 was 97.2% (1040/1070). Of the 30 participants who failed to attain SVR12, 15 relapsed and 15 had nonvirologic failure. Among participant subgroups, SVR12 was high in those with compensated cirrhosis (188/189, 99.5%), HIV co-infection (51/54, 94.4%), and baseline viral load > 800,000 IU/ml (705/728, 96.8%). Resistance-associated substitutions (RASs) at NS5A positions 28, 30, 31, or 93 were present in 21.6% of participants at baseline. SVR12 was 99.6% (820/823) in participants without baseline NS5A RASs and 94.7% (215/227) in those with baseline NS5A RASs. Serious adverse events occurred in 3.2% (34/1070) of participants, nine of which occurred after study medication was completed. CONCLUSIONS: Elbasvir/grazoprevir for 12 weeks represents an effective treatment option for participants with HCV GT1b infection. SVR12 was high in all participant subgroups, including those with compensated cirrhosis, HIV co-infection, and high baseline viral load. CLINICALTRIALS. GOV IDENTIFIERS: The trials discussed in this paper were registered with Clinicaltrial.gov as the following: NCT02092350 (C-SURFER), NCT02105662 (C-EDGE Co-Infection), NCT02105467 (C-EDGE treatment-naive), NCT02105701 (C-EDGE treatment-experienced), NCT01717326 (C-WORTHy), NCT02251990 (C-CORAL), NCT02105688 (C-EDGE COSTAR), NCT02252016 (C-EDGE IBLD), NCT02115321 (C-SALT), NCT02203149 (Japan phase 2/3 study), NCT02358044 (C-EDGE Head-2-Head).
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antivirové látky $x škodlivé účinky $x terapeutické užití $7 D000998
650    _2
$a benzofurany $x škodlivé účinky $x terapeutické užití $7 D001572
650    _2
$a klinické zkoušky, fáze II jako téma $7 D017322
650    _2
$a klinické zkoušky, fáze III jako téma $7 D017326
650    _2
$a koinfekce $x komplikace $7 D060085
650    _2
$a virová léková rezistence $x genetika $7 D024882
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a HIV infekce $x komplikace $7 D015658
650    _2
$a Hepacivirus $x genetika $7 D016174
650    _2
$a chronická hepatitida C $x komplikace $x farmakoterapie $x virologie $7 D019698
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $x škodlivé účinky $x terapeutické užití $7 D007093
650    _2
$a jaterní cirhóza $x patofyziologie $x virologie $7 D008103
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chinoxaliny $x škodlivé účinky $x terapeutické užití $7 D011810
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a setrvalá virologická odpověď $7 D000072230
650    _2
$a virová nálož $7 D019562
650    _2
$a virové nestrukturální proteiny $x genetika $7 D017361
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Serfaty, Lawrence $u Service d'Hépatologie, Hôpital Saint-Antoine, Université Pierre and Marie Curie, Paris, France.
700    1_
$a Vierling, John M. $7 xx0246231 $u Baylor College of Medicine, Advanced Liver Therapies, Houston, TX, USA.
700    1_
$a Cheng, Wendy $u Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, WA, Australia.
700    1_
$a George, Jacob $u Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.
700    1_
$a Sperl, Jan $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
700    1_
$a Strasser, Simone $u AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
700    1_
$a Kumada, Hiromitsu $u Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
700    1_
$a Hwang, Peggy $u Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Robertson, Michael $u Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Wahl, Janice $u Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Barr, Eliav $u Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Talwani, Rohit $u Merck & Co., Inc., Kenilworth, NJ, USA.
700    1_
$a Platt, Heather $u Merck & Co., Inc., Kenilworth, NJ, USA.
773    0_
$w MED00002687 $t Journal of gastroenterology $x 1435-5922 $g Roč. 53, č. 5 (2018), s. 679-688
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29344726 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20200330160717 $b ABA008
999    __
$a ok $b bmc $g 1433761 $s 1067072
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 53 $c 5 $d 679-688 $e 20180117 $i 1435-5922 $m Journal of gastroenterology $n J Gastroenterol $x MED00002687
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace